Bimatoprost Implant (Durysta™)

Durysta (bimatoprost implant) is covered only for the FDA‑approved indication—reduction of intraocular pressure in adults with open‑angle glaucoma or ocular hypertension—and re‑treatment of an eye previously treated with Durysta is excluded. Authorization requires the patient be ≥18, have documented inadequate efficacy or severe adverse events to ≥2 ophthalmic prostaglandins and to ≥2 ophthalmic products from two different pharmacologic classes, be prescribed by or in consultation with an ophthalmologist, and is limited to one implant per treated eye (maximum two implants per patient).

"Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension (FDA-approved indication)."

Sign up to see full coverage criteria, indications, and limitations.